Developer docs
API playgroundTry for free, no card

Search company profiles

GH Research

Full company profile

uuid0000j1h

Namestring
GH Research
Legal namestring
GH Research Ireland Limited
Websiteurl
ghres.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

GH Research PLC is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland, with operations in Ireland and clinical activity spanning the European Union, United Kingdom, and United States. Listed on NASDAQ under ticker GHRS since 2021, the company was founded in 2018 by Florian Schönharting and Magnus Halle, and currently operates with a headcount of 51-100 employees. The operating subsidiary, GH Research Ireland Limited, holds the development pipeline and intellectual property estate.

The company's core technology centers on a portfolio of proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates designed for ultra-rapid onset antidepressant activity. The platform comprises three delivery modalities: GH001 (proprietary pulmonary inhalation formulation, lead product), GH002 (intravenous formulation, Phase 1 completed in 64 healthy volunteers), and GH003 (intranasal formulation, early-stage). The lead mechanism — the Individualized Dosing Regimen (IDR) — allows single-day administration of up to three ascending doses (6 mg, 12 mg, 18 mg) by inhalation, achieving Day-8 remission rates of 53.9%-63.6% in Phase 2b treatment-resistant depression (TRD) and up to 85.7% in 6-month open-label follow-up, without the requirement for structured psychotherapy commonly associated with psychedelic protocols. Phase 2a studies in bipolar II disorder with depressive episode (n=6) and postpartum depression (n=10, 100% Day-8 remission) extend the platform's potential. The company is pursuing additional patents covering novel therapeutic uses, manufacturing methods, salt forms, aerosol compositions, and device-related aspects across multiple delivery routes.

GH Research is currently pre-revenue with no approved products and no commercial sales. Revenue generation is contingent on obtaining regulatory approval, with company-stated commercialization targeted around 2028 following a global Phase 3 pivotal program for GH001 in TRD that is planned to initiate in late 2026 (pending the FDA's January 2026 lifting of a clinical hold imposed in September 2023). Upon approval, distribution is anticipated through standard pharmaceutical supply chains to hospitals, specialty pharmacies, and psychiatric treatment centers. To date the company has financed operations through Series A and B rounds in 2020-2021, an upsized 2021 NASDAQ IPO, a $150 million underwritten offering in February 2025, a $117.5 million underwritten offering in April 2026, and a $200 million at-the-market facility with Stifel, Nicolaus & Company entered in May 2026, bringing pro forma liquidity to approximately $378.5 million and supporting operations through the planned Phase 3 readout window.

Short descriptiontext

GH Research is a clinical-stage biopharmaceutical company developing proprietary inhaled, intravenous, and intranasal mebufotenin (5-MeO-DMT) formulations for treatment-resistant depression, bipolar II disorder, and postpartum depression.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, mebufotenin therapies, treatment-resistant depression, psychedelic drug development, 5-MeO-DMT formulations
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Neuropsychiatric Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1No Commercial Revenue
TypeOne Time License
Description

GH Research is a clinical-stage biopharmaceutical company with no approved products or commercial revenue. The company is focused on developing its proprietary mebufotenin pipeline (GH001, GH002, GH003) through clinical trials, with the goal of obtaining regulatory approval for commercialization in treatment-resistant depression, bipolar II disorder, and postpartum depression. Potential future revenue would come from pharmaceutical product sales following regulatory approval.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GH Research develops proprietary mebufotenin (5-MeO-DMT) product candidates for the treatment of psychiatric and neurological disorders. Its lead candidate GH001 is a pulmonary inhalation formulation of mebufotenin advancing toward a global Phase 3 pivotal program for treatment-resistant depression, with additional programs in bipolar II disorder and postpartum depression. The company also has GH002 (intravenous mebufotenin) and GH003 (intranasal mebufotenin) in earlier-stage development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Phase 2b TRD: Placebo-adjusted MADRS reduction of -15.5 points at Day 8 (P<0.0001)
+7 more records
Product overview1 text field

GH Research is a clinical-stage pharmaceutical company developing a portfolio of novel mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates for psychiatric and neurological disorders. The product portfolio centers on three proprietary formulations: GH001 (inhaled mebufotenin, lead product for TRD, BDII, and PPD), GH002 (intravenous mebufotenin), and GH003 (additional intranasal/intravenous candidate). GH001 is the primary focus, having completed Phase 2b trials for treatment-resistant depression with Phase 3 initiation planned for 2026. The company is not yet commercial and has no marketed products.

Product and service1 record
1GH001 (Inhaled Mebufotenin)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage psychedelic therapeutics company developing deuterated psilocybin and DMT-based programs for depression and anxiety disorders. Comparable as an emerging psychedelic player targeting overlapping psychiatric indications.

TypeDirect peer
Description

Clinical-stage psychedelic mental health company developing COMP360 psilocybin therapy for treatment-resistant depression, with a Phase 3 program also in progress. Direct head-to-head competitor to GH001 in the same TRD patient population using a different psychedelic mechanism.

TypeBroad incumbent
Description

Global CNS specialty pharma with established depression franchises including vortioxetine (Trintellix). Comparable as a large CNS incumbent with sales infrastructure and lifecycle management expertise relevant to a TRD launch.

TypeBroad incumbent
Description

Large pharma with Vraylar (cariprazine) approved for depressive episodes associated with bipolar I and bipolar II disorder. Direct overlap with GH Research's BDII program as an established CNS incumbent in the same indication.

5MindMed
TypeDirect peer
Description

Public clinical-stage company developing psychedelic-inspired therapies (LSD, MDMA programs) for anxiety, depression, and other CNS indications. Direct peer competing for the same psychedelic-psychiatry opportunity with overlapping target indications.

TypeBroad incumbent
Description

Specialty CNS pharma with commercial franchises in neurology and psychiatry. Highly comparable as a specialty CNS company; notably, GH Research's co-founder Florian Schönharting co-founded Acadia, indicating deep category expertise.

7ATAI Life Sciences
TypeDirect peer
Description

Public clinical-stage platform holding multiple psychedelic mental health programs, including novel 5-MeO-DMT approaches in depression. Closely comparable as a psychedelic-focused holding company investing across multiple CNS assets.

TypeBroad incumbent
Description

Commercial-stage CNS specialty pharma with Auvelity (dextromethorphan/bupropion) approved for major depressive disorder and other CNS launches. Comparable as a specialty CNS company targeting the same depression prescribing audience with a more conventional oral therapy.

TypeBroad incumbent
Description

CNS specialty pharma with Zurzuvae approved for postpartum depression (same indication as GH001 PPD program) and prior depression programs. Most direct comparability to GH Research's PPD opportunity with an approved CNS asset.

TypeBroad incumbent
Description

Large pharma with Spravato (esketamine) — the only FDA-approved therapy specifically indicated for treatment-resistant depression. Sets the established standard of care that GH001 would compete against at launch.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GH Research

Clinical-Stage Neuropsychiatric Pharmaceuticalsghres.com

GH Research is a clinical-stage biopharmaceutical company developing proprietary inhaled, intravenous, and intranasal mebufotenin (5-MeO-DMT) formulations for treatment-resistant depression, bipolar II disorder, and postpartum depression.

What GH Research does

GH Research PLC is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland, with operations in Ireland and clinical activity spanning the European Union, United Kingdom, and United States. Listed on NASDAQ under ticker GHRS since 2021, the company was founded in 2018 by Florian Schönharting and Magnus Halle, and currently operates with a headcount of 51-100 employees. The operating subsidiary, GH Research Ireland Limited, holds the development pipeline and intellectual property estate.

The company's core technology centers on a portfolio of proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates designed for ultra-rapid onset antidepressant activity. The platform comprises three delivery modalities: GH001 (proprietary pulmonary inhalation formulation, lead product), GH002 (intravenous formulation, Phase 1 completed in 64 healthy volunteers), and GH003 (intranasal formulation, early-stage). The lead mechanism — the Individualized Dosing Regimen (IDR) — allows single-day administration of up to three ascending doses (6 mg, 12 mg, 18 mg) by inhalation, achieving Day-8 remission rates of 53.9%-63.6% in Phase 2b treatment-resistant depression (TRD) and up to 85.7% in 6-month open-label follow-up, without the requirement for structured psychotherapy commonly associated with psychedelic protocols. Phase 2a studies in bipolar II disorder with depressive episode (n=6) and postpartum depression (n=10, 100% Day-8 remission) extend the platform's potential. The company is pursuing additional patents covering novel therapeutic uses, manufacturing methods, salt forms, aerosol compositions, and device-related aspects across multiple delivery routes.

GH Research is currently pre-revenue with no approved products and no commercial sales. Revenue generation is contingent on obtaining regulatory approval, with company-stated commercialization targeted around 2028 following a global Phase 3 pivotal program for GH001 in TRD that is planned to initiate in late 2026 (pending the FDA's January 2026 lifting of a clinical hold imposed in September 2023). Upon approval, distribution is anticipated through standard pharmaceutical supply chains to hospitals, specialty pharmacies, and psychiatric treatment centers. To date the company has financed operations through Series A and B rounds in 2020-2021, an upsized 2021 NASDAQ IPO, a $150 million underwritten offering in February 2025, a $117.5 million underwritten offering in April 2026, and a $200 million at-the-market facility with Stifel, Nicolaus & Company entered in May 2026, bringing pro forma liquidity to approximately $378.5 million and supporting operations through the planned Phase 3 readout window.

GH Research firmographics

Firmographics
Name
GH Research
Legal name
GH Research Ireland Limited
Website
https://ghres.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
GH Research is a clinical-stage biopharmaceutical company developing proprietary inhaled, intravenous, and intranasal mebufotenin (5-MeO-DMT) formulations for treatment-resistant depression, bipolar II disorder, and postpartum depression.
Ownership category
akta.pro rank

GH Research industry classification

Industry
Product category
Clinical-Stage Neuropsychiatric Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage biopharmaceutical
  • Mebufotenin therapies
  • Treatment-resistant depression
  • Psychedelic drug development
  • 5-MeO-DMT formulations

Where GH Research is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

GH Research business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. No Commercial Revenue: GH Research is a clinical-stage biopharmaceutical company with no approved products or commercial revenue. The company is focused on developing its proprietary mebufotenin pipeline (GH001, GH002, GH003) through clinical trials, with the goal of obtaining regulatory approval for commercialization in treatment-resistant depression, bipolar II disorder, and postpartum depression. Potential future revenue would come from pharmaceutical product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

GH Research product offering

Product offering

Core offering

GH Research develops proprietary mebufotenin (5-MeO-DMT) product candidates for the treatment of psychiatric and neurological disorders. Its lead candidate GH001 is a pulmonary inhalation formulation of mebufotenin advancing toward a global Phase 3 pivotal program for treatment-resistant depression, with additional programs in bipolar II disorder and postpartum depression. The company also has GH002 (intravenous mebufotenin) and GH003 (intranasal mebufotenin) in earlier-stage development.

Product overview

GH Research is a clinical-stage pharmaceutical company developing a portfolio of novel mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates for psychiatric and neurological disorders. The product portfolio centers on three proprietary formulations: GH001 (inhaled mebufotenin, lead product for TRD, BDII, and PPD), GH002 (intravenous mebufotenin), and GH003 (additional intranasal/intravenous candidate). GH001 is the primary focus, having completed Phase 2b trials for treatment-resistant depression with Phase 3 initiation planned for 2026. The company is not yet commercial and has no marketed products.

Differentiator

Problem solved

Functional benefit

Products and services

  • GH001 (Inhaled Mebufotenin)

Quantifiable outcome

  • Phase 2b TRD: Placebo-adjusted MADRS reduction of -15.5 points at Day 8 (P<0.0001)
  • +7 more outcomes

Companies that use GH Research

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

GH Research technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

GH Research partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

GH Research competitors and assessment

Company assessment

Emerging players

  • Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin and DMT-based programs for depression and anxiety disorders. Comparable as an emerging psychedelic player targeting overlapping psychiatric indications.

Direct peers

  • Compass Pathways: Clinical-stage psychedelic mental health company developing COMP360 psilocybin therapy for treatment-resistant depression, with a Phase 3 program also in progress. Direct head-to-head competitor to GH001 in the same TRD patient population using a different psychedelic mechanism.
  • MindMed: Public clinical-stage company developing psychedelic-inspired therapies (LSD, MDMA programs) for anxiety, depression, and other CNS indications. Direct peer competing for the same psychedelic-psychiatry opportunity with overlapping target indications.
  • ATAI Life Sciences: Public clinical-stage platform holding multiple psychedelic mental health programs, including novel 5-MeO-DMT approaches in depression. Closely comparable as a psychedelic-focused holding company investing across multiple CNS assets.

Broad incumbents

  • Lundbeck: Global CNS specialty pharma with established depression franchises including vortioxetine (Trintellix). Comparable as a large CNS incumbent with sales infrastructure and lifecycle management expertise relevant to a TRD launch.
  • AbbVie: Large pharma with Vraylar (cariprazine) approved for depressive episodes associated with bipolar I and bipolar II disorder. Direct overlap with GH Research's BDII program as an established CNS incumbent in the same indication.
  • Acadia Pharmaceuticals: Specialty CNS pharma with commercial franchises in neurology and psychiatry. Highly comparable as a specialty CNS company; notably, GH Research's co-founder Florian Schönharting co-founded Acadia, indicating deep category expertise.
  • Axsome Therapeutics: Commercial-stage CNS specialty pharma with Auvelity (dextromethorphan/bupropion) approved for major depressive disorder and other CNS launches. Comparable as a specialty CNS company targeting the same depression prescribing audience with a more conventional oral therapy.
  • Sage Therapeutics: CNS specialty pharma with Zurzuvae approved for postpartum depression (same indication as GH001 PPD program) and prior depression programs. Most direct comparability to GH Research's PPD opportunity with an approved CNS asset.
  • Johnson & Johnson: Large pharma with Spravato (esketamine) — the only FDA-approved therapy specifically indicated for treatment-resistant depression. Sets the established standard of care that GH001 would compete against at launch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

GH Research social profiles

Digital presence

GH Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GH Research leadership team

Management profile

Number of profiles

Profiles8 records

GH Research funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GH Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GH Research

What does GH Research do?

GH Research develops proprietary mebufotenin (5-MeO-DMT) product candidates for the treatment of psychiatric and neurological disorders. Its lead candidate GH001 is a pulmonary inhalation formulation of mebufotenin advancing toward a global Phase 3 pivotal program for treatment-resistant depression, with additional programs in bipolar II disorder and postpartum depression. The company also has GH002 (intravenous mebufotenin) and GH003 (intranasal mebufotenin) in earlier-stage development.

Is GH Research a public or private company?

GH Research is a public company. It is classified as public and is currently operating.

When was GH Research founded?

GH Research was founded in 2018. It employs 51 to 100 people.

Where is GH Research based?

GH Research is headquartered in Dublin, Ireland, in the Europe region.

How does GH Research make money?

One revenue line is on record: no Commercial Revenue.

Who are GH Research's main competitors?

Cybin is listed as an emerging player. Direct peers are Compass Pathways, MindMed and ATAI Life Sciences. Broad incumbents are Lundbeck, AbbVie, Acadia Pharmaceuticals, Axsome Therapeutics, Sage Therapeutics and Johnson & Johnson.

Does GH Research have an API?

No public API is recorded for GH Research.

What industry is GH Research in?

GH Research's product category is Clinical-Stage Neuropsychiatric Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewGuggenheim maintains GH Research at Buy, raises price target to $46 from $40Guggenheim maintained GH Research at Buy and raised its price target to $46 from $40, a 15% increase. The target implies 151.8% upside from the Nov 17 close of $18.27.TradingViewHC Wainwright & Co. maintains GH Research at Buy, lowers price target to $55 from $65HC Wainwright & Co. maintained GH Research at Buy and lowered its price target to $55 from $65, a 15.4% decrease. The target implies an upside of 193.3% from the Nov 16 close of $18.75.TradingViewKey facts: GH Research Plc Cash $350.6M; Buy Target $45.80GH Research Plc reported $350.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, up from $280.7 million a year earlier. Analysts raised the average 12-month price target to $45.80, with a Buy consensus and forecasts ranging from $39 to $65.TradingViewGH Research PLC Stock 12‑Month Price Target Raised to $45.8, Implies 140% UpsideAnalysts' average price target for GH Research PLC rose to $45.8 from $41.7, implying about 140% upside from the Nov. 13 closing price. The consensus remains a Buy across six analysts, with forecasts ranging from $39 to $65 per share.Tech TimesPsychedelic Depression Drug GH001 Gets Initial FDA Feedback; Lilly-Owned Rival Advances Phase 3 WorkGH Research received positive initial FDA feedback on its pivotal trial design for GH001, an inhaled psychedelic for treatment-resistant depression, but no pivotal trial has started. The rival AtaiBeckley's nasal-spray BPL-003 has initiated Phase 3, with Lilly's purchase worth up to $3.8 billion. GH Research's End-of-Phase 2 meeting is not due until Q1 2027.Seeking AlphaGH Research GAAP EPS of -$0.18 beats by $0.13GH Research reported Q3 GAAP EPS of -$0.18, beating by $0.13. As of September 30, 2026, the company held $350.6 million in cash, cash equivalents, and marketable securities.Investing.comStifel reiterates GH Research stock rating on FDA alignmentStifel reiterated a Buy rating and $38 price target on GH Research after the company preliminarily aligned with the FDA on a Phase 3 trial design. The design uses a next-generation inhalation device, matching Phase 2 efficacious doses of 12 and 18 mg, with a four-week primary endpoint. GH Research plans another FDA meeting in Q1, with study start expected shortly after.TradingViewGH Research PLC (GHRS) Appoints CDO to Lead GH001 Pivotal ProgramsGH Research appointed Vanina Popova as Chief Development Officer to lead clinical development of GH001 into pivotal programs for treatment-resistant and postpartum depression. She brings over 20 years of R&D experience, including leading the pivotal Phase 3 trial that supported Spravato's approval in TRD.American Banking and Market NewsGH Research PLC $GHRS Stock: CenterBook Partners LP Lowers PositionCenterBook Partners LP trimmed its GH Research stake by 62.2% in Q3, selling 43,178 shares and holding 26,258 shares worth $617,000. Other funds like Troluce Capital and Braidwell LP also adjusted positions, while analysts rate the stock a Moderate Buy with a $45 consensus target.American Banking and Market NewsGH Research PLC (GHRS) – What Are Brokerages Saying About This Stock?Analysts rate GH Research PLC with an average 'Moderate Buy' and a $45 price target. The company reported a loss of $0.23 per share, beating estimates, and institutional investors hold 56.9% of the stock. GH Research develops psychedelic-based therapies for psychiatric disorders.